Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
- Conditions
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01934894
- Locations
- πΊπΈ
Florida Cancer Specialists - South, Fort Myers, Florida, United States
πΊπΈOncology Hematology Care Inc., Cincinnati, Ohio, United States
πΊπΈFlorida Cancer Specialists-North, Saint Petersburg, Florida, United States
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT01871675
- Locations
- πΊπΈ
Florida Cancer Specialists, Sarasota, Florida, United States
πΊπΈTennessee Oncology, PLLC, Nashville, Tennessee, United States
πΊπΈOklahoma University, Oklahoma City, Oklahoma, United States
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01848145
- Locations
- πΊπΈ
Colorado Blood Cancer Institute, Denver, Colorado, United States
πΊπΈFlorida Cancer Specialists-North, Saint Petersburg, Florida, United States
πΊπΈFlorida Cancer Specialists-South, Fort Myers, Florida, United States
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 132
- Registration Number
- NCT01844817
- Locations
- πΊπΈ
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
πΊπΈFlorida Hospital Cancer Insitute, Orlando, Florida, United States
πΊπΈIngalls Cancer Research Center, Harvey, Illinois, United States
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 155
- Registration Number
- NCT01829113
- Locations
- πΊπΈ
Tennessee Oncology, Nashville, Tennessee, United States
πΊπΈFlorida Cancer Specialists-South, Fort Myers, Florida, United States
πΊπΈOncology Hematology Care, Inc., Cincinnati, Ohio, United States
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01769508
- Locations
- πΊπΈ
Tennessee Oncology, Nashville, Tennessee, United States
πΊπΈFlorida Cancer Specialists-North, St. Petersburg, Florida, United States
πΊπΈChattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT01749956
- Locations
- πΊπΈ
Virginia Cancer Institute, Richmond, Virginia, United States
πΊπΈBaptist Hospital East, Louisville, Kentucky, United States
πΊπΈSpace Coast Cancer Center, Titusville, Florida, United States
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT01626352
- Locations
- πΊπΈ
Woodlands Medical Specialists, Pensacola, Florida, United States
πΊπΈFlorida Cancer Specialists North, Saint Petersburg, Florida, United States
πΊπΈSpace Coast Cancer Center, Titusville, Florida, United States
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT01611857
- Locations
- πΊπΈ
Yale University School of Medicine, New Haven, Connecticut, United States
πΊπΈFlorida Cancer Specialists-Sarasota, Sarasota, Florida, United States
πΊπΈFlorida Cancer Specialists-North, St. Petersburg, Florida, United States
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT01527487
- Locations
- πΊπΈ
Woodlands Medical Specialists, Pensacola, Florida, United States
πΊπΈNebraska Methodist Cancer Center, Omaha, Nebraska, United States
πΊπΈNortheast Georgia Medical Center, Gainesville, Georgia, United States